PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

9903747-5 IPOS copy

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 241/20, 241/26, A61K 31/495 | A1

(11) International Publication Number: WO 98/38174

(43) International Publication Date: 3 September 1998 (03.09.98)

(21) International Application Number: PCT/EP98/01077

(22) International Filing Date: 26 February 1998 (26.02.98)

(30) Priority Data:
9704275.8 1 March 1997 (01.03.97) GB
9708183.0 23 April 1997 (23.04.97) GB

(71) Applicant *(for all designated States except US)*: GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: COX, Brian [GB/GB]; Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Herts SG1 2NY (GB). NOBBS, Malcolm, Stuart [GB/GB]; Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Herts SG1 2NY (GB). SHAH, Gita, Punjabhai [GB/GB]; Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Herts SG1 2NY (GB). EDNEY, Dean, David [GB/GB]; Glaxo Wellcome plc, Temple Hill, Dartford, Kent DA1 5AH (GB). LOFT, Michael, Simon [GB/GB]; Glaxo Wellcome plc, Temple Hill, Dartford, Kent DA1 5AH (GB).

(74) Agent: VOLCKMAN, Janis, Florence; Glaxo Wellcome plc, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).


(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published


With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: PYRAZINE COMPOUNDS



(I)



(a)

(57) Abstract

A compound of formula (I) wherein R^1 is selected from the group consisting of phenyl substituted by one or more halogen atoms, naphthyl and naphthyl substituted by one or more halogen atoms; R^2 is selected from the group consisting of $-NH_2$ and $-NHC(=O)R^a$; R^3 is selected from the group consisting of $-NR^bR^c$, $-NHC(=O)R^a$ and hydrogen, R^4 is selected from the group consisting of hydrogen, $-C_{1-4}$ alkyl, $-C_{1-4}$ alkyl substituted by one or more halogen atoms, $-CN$, $-CH_2OH$, $-CH_2OR^d$ and $-CH_2S(O)_x R^d$; wherein R^a represents C_{1-4} alkyl or C_{3-7}cycloalkyl, and R^b and R^c, which may be the same or different, are selected from hydrogen and C_{1-4} alkyl, or together with the nitrogen atom to which they are attached, form a 6-membered nitrogen containing heterocycle, which heterocycle can be further susbtituted with one or more C_{1-4} alkyl; R^d is selected from C_{1-4} alkyl or C_{1-4} alkyl substituted by one or more halogen atoms; x is an integer zero, one or two; and pharmaceutically acceptable derivatives thereof; with the proviso that R^1 does not represent (a); when R^2 is $-NH_2$, and both R^3 and R^4 are hydrogen.